Boston Scientific completes enrollment for aortic valve trial; Diagnostics startup Aggredyne raises $3M;

@FierceMedDev: 1,500 new construction jobs as IDA-backed investments ramp up--via SiliconRepublic. News | Follow @FierceMedDev

> Boston Scientific ($BSX) has completed enrollment for its REPRISE I trial, which is evaluating the safety of its Lotus aortic valve system. Release

> Diagnostics startup Aggredyne has raised $3 million in a Series A convertible preferred stock financing round. The company will use the money to add staff and gear up for a 510(k) filing for its lead product. Release

> Additional diagnostics tests are needed to help differentiate Alzheimer's disease cases with mixed pathology, University of Pennsylvania scientists have discovered. Release

> Delcath Systems ($DCTH), a specialty medical device and pharmaceutical company focused on cancer treatment, has closed a $20 million line of credit with Silicon Valley Bank to support growth and product development. Release

> Wakefield, MA-based ActiViews has gained 510(k) clearance for its flagship product, a needle guidance system designed for such CT-guided interventional procedures as biopsies and ablations.  Release

Biotech News

@FierceBiotech: Survey: Pharma lags peers in gaining trust via social media. Article | Follow @FierceBiotech

@JohnCFierce: Biota (Australia) to merge into U.S. biotech Nabi and move to U.S. Release | Follow @JohnCFierce

@RyanMFierce: Nice visualization of biotech VC trends dating back to '95. Graphics | Follow @RyanMFierce

> AstraZeneca reels in promising PhIII gout drug in $1.26B Ardea buyout. More

> Biotech VC deals, dollars shrivel in Q1 as devices see an upturn. Report

> Pike picked to sit at Quintiles peak. Item

Pharma News

@FiercePharma: Will lame-duck Congress go after pharma's advertising deduction? Ad lobbyists keeping an eye--AdAge. More | Follow @FiercePharma

> Amylin's up for bid. Who'll step in line? Article

> Pfizer gets $11.85B in nutrition sale to Nestlé. Item

> China sweeps up dozens in whirlwind drug-capsule probe. Report

> Novartis blueprints $550M Swiss drug plant after layoffs backlash. Story

> FDA prioritizes post-marketing drug safety, report says. Report

Biotech IT News

> NextBio moves genetic analysis software into clinical R&D territory. News

> Survey: Pharma lags peers in gaining trust via social media. More

> GAO report: FDA's IT modernization 'in jeopardy'. Story

> Google VC fuels Series A round for pharma software startup. Article

And Finally... The FDA is warning that consumer products using nanotechnology, such as skin creams, may require additional safety tests. Story